a complimentary source PDF.
... preventable by blood pressure reduction, so the estimate of the reduction in stroke was taken from the trials in which participants had coronary artery disease without recent infarction or heart failure. We also categorised the trials into “blood pressure difference trials” and “drug comparison tria ...
... preventable by blood pressure reduction, so the estimate of the reduction in stroke was taken from the trials in which participants had coronary artery disease without recent infarction or heart failure. We also categorised the trials into “blood pressure difference trials” and “drug comparison tria ...
pharmacokinetics, tissue distribution, metabolism, and excretion of
... gene has been shown to increase in certain inflammatory states. These data led to the hypothesis that specific COX-2 inhibitors would have the anti-inflammatory efficacy of traditional nonsteroidal anti-inflammatory drugs but not adverse effects in the GI tract and platelet (Masferrer et al., 1994; ...
... gene has been shown to increase in certain inflammatory states. These data led to the hypothesis that specific COX-2 inhibitors would have the anti-inflammatory efficacy of traditional nonsteroidal anti-inflammatory drugs but not adverse effects in the GI tract and platelet (Masferrer et al., 1994; ...
Topiramate in Migraine Prevention
... dose of 100mg/d. A common side effect seen with topiramate is paresthesia, however, this will normally go away after a few days. Cognitive side effects appear in 8–10% of patients, which can potentially restrict the use of topiramate. These persistent cognitive problems include memory problems and p ...
... dose of 100mg/d. A common side effect seen with topiramate is paresthesia, however, this will normally go away after a few days. Cognitive side effects appear in 8–10% of patients, which can potentially restrict the use of topiramate. These persistent cognitive problems include memory problems and p ...
G6PD deficiency: a classic example of pharmacogenetics with
... they did not come to any other harm, they all recovered without any blood transfusion and, like after an attack of favism, there is no reason to presume that they had any long-term ill effects. One of us has known in person some of the physicians involved, and regards them as of high moral standards ...
... they did not come to any other harm, they all recovered without any blood transfusion and, like after an attack of favism, there is no reason to presume that they had any long-term ill effects. One of us has known in person some of the physicians involved, and regards them as of high moral standards ...
Etopophos and associated names - Art. 30 referral
... ETOPOPHOS and associated names should only be administered and monitored under the supervision of a qualified physician experienced in the use of anti-neoplastic medicinal products. In all instances where the use of ETOPOPHOS and associated names is considered for chemotherapy, the physician must ev ...
... ETOPOPHOS and associated names should only be administered and monitored under the supervision of a qualified physician experienced in the use of anti-neoplastic medicinal products. In all instances where the use of ETOPOPHOS and associated names is considered for chemotherapy, the physician must ev ...
Ann. Emerg. Safty of phenylpropanolismine. 66 b.
... Two groups of volunteers, 32 and 6 respectively, were given capsules containing (1) phenylpropanolam ine 50 mg in sustained action (SA) form (2) PPA 50 mg as SA plus belladonna alkaloids 0.25 mg and (3) a placebo. Each test product was taken for a period of --1 week by the group of 32 volunteers who ...
... Two groups of volunteers, 32 and 6 respectively, were given capsules containing (1) phenylpropanolam ine 50 mg in sustained action (SA) form (2) PPA 50 mg as SA plus belladonna alkaloids 0.25 mg and (3) a placebo. Each test product was taken for a period of --1 week by the group of 32 volunteers who ...
Fentanyl Buccal Lozenges (Actiq®)
... fentanyl buccal film dose has been determined, the patient should receive a prescription for the effective dosage strength and use or dispose of the remaining unused 200 mcg films. Fentanyl buccal films should not be torn or cut prior to use and will dissolve within 15 to 30 minutes following applic ...
... fentanyl buccal film dose has been determined, the patient should receive a prescription for the effective dosage strength and use or dispose of the remaining unused 200 mcg films. Fentanyl buccal films should not be torn or cut prior to use and will dissolve within 15 to 30 minutes following applic ...
Biodegradable Janus Nanoparticles for Local Pulmonary Delivery of
... particles designed to load anticancer drugs for lung cancer treatment by inhalation. The particles were synthesized using binary mixtures of biodegradable and biocompatible materials. The particles did not demonstrate cyto- and genotoxic effects. Janus particles were internalized by cancer cells and ...
... particles designed to load anticancer drugs for lung cancer treatment by inhalation. The particles were synthesized using binary mixtures of biodegradable and biocompatible materials. The particles did not demonstrate cyto- and genotoxic effects. Janus particles were internalized by cancer cells and ...
University of Groningen Species and strain differences in drug
... to realize that humans differ from animals with regard to isoform composition, expression and catalytic activities of drug metabolizing enzymes. In this review we aim to describe similarities and differences in this respect among the different species, including man. This may be helpful for drug res ...
... to realize that humans differ from animals with regard to isoform composition, expression and catalytic activities of drug metabolizing enzymes. In this review we aim to describe similarities and differences in this respect among the different species, including man. This may be helpful for drug res ...
Product Monograph
... discontinuation. The risk of discontinuation symptoms may be dependent on several factors, including the duration and dose of therapy and the rate of dose reduction. Dizziness, sensory disturbances (including paraesthesia), sleep disturbances (including insomnia and intense dreams), agitation or anx ...
... discontinuation. The risk of discontinuation symptoms may be dependent on several factors, including the duration and dose of therapy and the rate of dose reduction. Dizziness, sensory disturbances (including paraesthesia), sleep disturbances (including insomnia and intense dreams), agitation or anx ...
Full Text PDF
... to induce flare-up of chronic psoriasis or development of pustular psoriasis. Here we report a psoriatic patient who developed pustular eruptions in four weeks after treatment with terbinafine for his presumptive tinia unguium without a definitive mycological evidence. The skin eruptions progressed ...
... to induce flare-up of chronic psoriasis or development of pustular psoriasis. Here we report a psoriatic patient who developed pustular eruptions in four weeks after treatment with terbinafine for his presumptive tinia unguium without a definitive mycological evidence. The skin eruptions progressed ...
Background Chapter 6.3 - WHO archives
... evidence base. Furthermore, with clearly additive beneficial effects on the risks of serious vascular events and death, there is a very strong rationale for the combined use of these three key interventions. A clinical innovation that resulted in the more appropriate, widespread and sustained use of ...
... evidence base. Furthermore, with clearly additive beneficial effects on the risks of serious vascular events and death, there is a very strong rationale for the combined use of these three key interventions. A clinical innovation that resulted in the more appropriate, widespread and sustained use of ...
Curcuminoid drug interactions
... valuable in the prevention and treatment of many different degenerative diseases. As curcuminoids are often taken as supplements by some population groups, it may be asked whether this can lead to changes in the pharmacokinetics or pharmacodynamics of other drugs taken at the same time. It is partic ...
... valuable in the prevention and treatment of many different degenerative diseases. As curcuminoids are often taken as supplements by some population groups, it may be asked whether this can lead to changes in the pharmacokinetics or pharmacodynamics of other drugs taken at the same time. It is partic ...
Impurities in new drug products, Q3B (R2)
... thresholds would be considered on a case-by-case basis. The "Decision Tree for Identification and Qualification of a Degradation Product" (Attachment 3) describes considerations for the qualification of degradation products when thresholds are exceeded. In some cases, reducing the level of degradati ...
... thresholds would be considered on a case-by-case basis. The "Decision Tree for Identification and Qualification of a Degradation Product" (Attachment 3) describes considerations for the qualification of degradation products when thresholds are exceeded. In some cases, reducing the level of degradati ...
fluphenazine and perphenazine impact on melanogenesis and
... Medical University of Silesia in Katowice, Department of Pharmaceutical Chemistry, JagielloÒska 4, 41-200 Sosnowiec, Poland Abstract: Fluphenazine and perphenazine as a phenothiazine-class antipsychotic drugs are widely used to treat psychoses and schizophrenia, however their use is associated with ...
... Medical University of Silesia in Katowice, Department of Pharmaceutical Chemistry, JagielloÒska 4, 41-200 Sosnowiec, Poland Abstract: Fluphenazine and perphenazine as a phenothiazine-class antipsychotic drugs are widely used to treat psychoses and schizophrenia, however their use is associated with ...
Cleocin Pediatric
... can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible. Laboratory Tests During prolonged therapy, periodic live ...
... can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible. Laboratory Tests During prolonged therapy, periodic live ...
Should I Enter a Clinical Trial? A Patient Reference
... care to individual patients. This Patient Reference Guide includes a summary of ECRI’s technical report that evaluated the available research evidence about (1) why patients enter clinical trials and (2) how well patients who receive medical care in a clinical trial do compared to patients treated f ...
... care to individual patients. This Patient Reference Guide includes a summary of ECRI’s technical report that evaluated the available research evidence about (1) why patients enter clinical trials and (2) how well patients who receive medical care in a clinical trial do compared to patients treated f ...
(BEN®) Patient Enrollment Form
... following administration in patients with HAE. Risk factors may include the presence of an indwelling venous catheter/access device, prior history of thrombosis, underlying atherosclerosis, use of oral contraceptives or certain androgens, morbid obesity, and immobility. Benefits of treatment of HAE ...
... following administration in patients with HAE. Risk factors may include the presence of an indwelling venous catheter/access device, prior history of thrombosis, underlying atherosclerosis, use of oral contraceptives or certain androgens, morbid obesity, and immobility. Benefits of treatment of HAE ...
Effects of Smoking on the Pharmacokinetics of Erlotinib
... subject’s smoking status. Following each single dose erlotinib administration, the subjects stayed in the clinic for at least 48 hours. Pharmacokinetic methods. Eleven plasma sampling times were used to determine the pharmacokinetic profile for each subject (predose, 1, 2, 4, 6, 8, 12, 24, 36, 48, a ...
... subject’s smoking status. Following each single dose erlotinib administration, the subjects stayed in the clinic for at least 48 hours. Pharmacokinetic methods. Eleven plasma sampling times were used to determine the pharmacokinetic profile for each subject (predose, 1, 2, 4, 6, 8, 12, 24, 36, 48, a ...
Product Monograph - AstraZeneca Canada
... The safety of BYDUREON was assessed in nine 24 to 30 week comparator-controlled trials (n = 2045) and two 10 and 15 week placebo-controlled studies (n = 51), with a total of 2096 patients with type 2 diabetes. In these trials, the most commonly observed adverse events in BYDUREON-treated patients we ...
... The safety of BYDUREON was assessed in nine 24 to 30 week comparator-controlled trials (n = 2045) and two 10 and 15 week placebo-controlled studies (n = 51), with a total of 2096 patients with type 2 diabetes. In these trials, the most commonly observed adverse events in BYDUREON-treated patients we ...
Aalborg Universitet The medication process in a psychiatric hospital Mainz, Jan
... The observational unit: The individual handling of medication (prescribing, dispensing, and administering). Results: In total, 189 errors were detected in 1,082 opportunities for error (17%) of which 84/998 (8%) were assessed as potentially harmful. The frequency of errors was: prescribing, 10/189 ( ...
... The observational unit: The individual handling of medication (prescribing, dispensing, and administering). Results: In total, 189 errors were detected in 1,082 opportunities for error (17%) of which 84/998 (8%) were assessed as potentially harmful. The frequency of errors was: prescribing, 10/189 ( ...
Full Text - Universiteit Leiden
... This thesis is divided into four parts. The first part aims at identifying obstacles and possible solutions for the clinical implementation of pharmacogenetics. In the second part, issues related to the quality control of pharmacogenetic testing are discussed. In the third part the influence of gene ...
... This thesis is divided into four parts. The first part aims at identifying obstacles and possible solutions for the clinical implementation of pharmacogenetics. In the second part, issues related to the quality control of pharmacogenetic testing are discussed. In the third part the influence of gene ...
OSAFLEX 1178 mg powder for oral solution, sachet ENG
... After oral administration of 14C-labelled glucosamine, the radioactivity is rapidly and almost completely (about 90%) absorbed systemically in healthy volunteers. The absolute bioavailability of glucosamine in man after administration of oral glucosamine sulfate was 44%, due to first-pass effect of ...
... After oral administration of 14C-labelled glucosamine, the radioactivity is rapidly and almost completely (about 90%) absorbed systemically in healthy volunteers. The absolute bioavailability of glucosamine in man after administration of oral glucosamine sulfate was 44%, due to first-pass effect of ...
2.7.3 Emulgent-free nanoporous/nanoparticulate
... device was primarily affected by the morphology and surface roughness (asperity size and density) of the particles but not by dispersive surface energies. The preparation of coated particles involving several production steps, such as those used by Pilcer et al. [10] and Raula et al. [11], might not ...
... device was primarily affected by the morphology and surface roughness (asperity size and density) of the particles but not by dispersive surface energies. The preparation of coated particles involving several production steps, such as those used by Pilcer et al. [10] and Raula et al. [11], might not ...